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ABSTRACT 
Pulmonary arterial hypertension (PAH) is a syndrome based on diverse 
etiologies and pathogenesis, potentially leading to right ventricular heart failure and 
death. Neuregulin (NRG)-1 has been implicated in several physiological processes 
regulating cardiac development, as well as cardiac and vascular homeostasis. 
Following the notion that NRG-1 has protective effects on the myocardium and 
vasculature, the question arises whether pharmacological NRG-1/ErbB activation has 
any therapeutic potential in PAH and ventricular dysfunction. Thus, in this study we 
investigated the effects of recombinant human (rh) NRG-1 treatment in PAH and its 
repercussion in myocardial function, in an animal model of monocrotaline (MCT)-
induced PAH.  
 Male Wistar rats randomly received MCT or vehicle. After 14 days, animals 
were randomly assigned to receive treatment with either rhNRG-1 or vehicle. The study 
resulted in 4 groups: CTRL, CTRL+rhNRG, MCT and MCT+rhNRG. 
Echocardiographic, ventricular invasive hemodynamic studies and sample collection for 
vascular and cardiomyocyte functional studies, as well as for morphometric, 
histological, and molecular studies were performed 21 to 24 days after MCT 
administration. 
 MCT animals developed PAH, demonstrated by impaired pulmonary flow, 
increased RV systolic pressures and decreased cardiac output. These changes were 
attenuated with rhNRG-1 treatment. Cardiomyocyte passive tension increase and 
impaired pulmonary endothelial function and structure, observed in the MCT group, 
were both reduced in the MCT + rhNRG-1 group.  
Administration of MCT resulted in RV hypertrophy, both at the whole heart and 
at the cardiomyocyte level, concomitant with increased fibrosis. Treating MCT animals 
with rhNRG-1 decreased overall hypertrophy and fibrosis. 
 PAH animals presented increased cardiac expression of brain natriuretic 
peptide and endothelin-1, as well as decreased levels of NRG-1. rhNRG-1 treatment 
abrogated these changes. 
In conclusion, we show that rhNRG-1 treatment is able to restore PAH-induced 
severe abnormalities in cardiopulmonary function. These findings suggest that the 
NRG-1 pathway has a relevant role on the pathophysiology of PAH and right 
ventricular function, representing a potential therapeutic target. 
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INTRODUCTION 
 
Pulmonary hypertension historical perspective 
The first case report of what later came up to be primary pulmonary 
hypertension (PPH), was made in 1891, by Ernst von Romberg. Once he was unable 
to determine any cause for the abnormalities in the pulmonary vessels observed in 
patients, he designated these vascular alterations as “pulmonary vascular sclerosis” 
[1]. “Ayerza’s disease” rose up, in 1901, as the name for PPH and right ventricular 
failure, and was believed to be caused by syphilis.  
During the next four decades, arteritis of the pulmonary arteries caused by 
syphilis infection continued to be the explanation [2] for the observed vascular 
abnormalities, until a British histopathologist, Oscar Brenner, in the 1940s, discredited 
Ayerza’s disease and the etiology proposed for it. He described that PPH was a result 
of histopathological changes in the small muscular arteries and arterioles [3], although 
he failed to relate the vasoconstriction associated with arterial remodelling and right 
ventricular hypertrophy and dilation.  
In 1951 the first description of PPH’s pathophysiology arose, when Dresdale 
and coworkers demonstrated that a patient with PPH  presented drastically lowered 
pulmonary arterial pressures when infused with a systemic vasodilator [4], being later 
corroborated with a pulmonary-targeted vasodilator [5]. 
After a surge of pulmonary hypertension (PH), between the late 60’s and early 
70’s, associated with the ingestion of aminorex fumarate [6], an appetite suppressant, 
interest was heightened in the pathophysiology of this disease, leading to a meeting of 
the World Health Organization (WHO) based on PPH, in 1975, which created the 
standards for diagnosis, data collection, exploration of new therapies, cooperation 
between research centres and promotion of public awareness of the disease. 
A second WHO meeting (1998) led to the creation of a clinical classification for 
all diseases associated with PH. In 2003, the classification was re-evaluated and in 
2008, the 4th WHO meeting led to the latest classification of PH, defining PAH and non-
PAH pulmonary hypertension categories (Table 1). 
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Table 1. Updated Clinical Classification of Pulmonary Hypertension (Dana Point, 2008) 
Pulmonary arterial hypertension 
(PAH) 
Non-PAH pulmonary hyper tension (PH) 
Well defined cause Unclear or multifactorial 
PAH (1) Left-heart disease (2) Unclear/multifactorial mechanisms (5) 
  Idiopathic   Systolic dysfunction   Haematologic disorders 
  Hereditary   Diastolic dysfunction     Myeloproliferative disorders, etc. 
  Drug/toxin induced   Valvular disease   Systemic disorders 
  Disease associated Lung diseases/hypoxia (3)     Vasculitis, sarcoidosis, neuro fibromatosis, etc. 
    CTD   COPD   Metabolic disorders 
    HIV infection   Interstitial lung disease     Glycogen storage disease , thyroid disorders , 
etc. 
    Portal hypertension   Sleep-disordered 
breathing 
  Congenital heart disease 
    Systemic-pulmonary shunts   Chronic exposure to high 
altitude 
    (Other than systemic-pulmonary shunt) 
    Schistosomiasis   Broncho pulmonary 
dysplasia 
  Other 
    Chronic haemolytic anaemia   Developmental 
abnormalities 
    Fibrosing mediastinitis , chronic renal failure on 
dialysis , etc. 
 Subclass of PAH (1′ ) CTEPH (4)  
  PVOD and PCH   
Classes are presented between parentheses. CTD - connective tissue disorder; HIV – human immunodeficiency virus; 
PVOD – pulmonary veno-occlusive disease; PCH - pulmonary capillary angiomatosis; COPD – chronic obstructive 
pulmonary disease; CTEPH – chronic thromboembolic PH. (adapted from Lourenço, AP et al, 2012 [7]) 
 
In Dana Point, the diagnostic criteria were updated and PH is now defined as a 
mean pulmonary arterial pressure higher than 25 mmHg at rest [8]. 
 
PAH pathophisiology 
 PAH is seriously underdiagnosed, and in spite a couple of population studies 
estimated the incidence and prevalence of PAH to be 2.4-7.6 cases/million/year and 
15-26 cases/million, respectively [9,10], worldwide the numbers would definitely go up, 
especially with its new association with other pathologies [7]. Besides PAH, non-PAH 
PH is also taking a more worrisome role since heart failure (HF) is the most frequent 
cause of PH [7]. Sixty percent of patients with severe left ventricular (LV) dysfunction, 
as well as 70% of patients with HF with normal ejection fraction (HFNEF) develop PH 
[11,12]. In 2020, the 3rd cause of death will be COPD, with associated right ventricular 
(RV) HF [13]. 
 PAH is a syndrome which results in restricted blood flow through the pulmonary 
arteries, leading to an increase in pulmonary vascular resistances (PVR) and 
consequently to RVHF. PVR is increased through vascular remodelling, which is 
caused by excessive cell proliferation and impaired apoptosis, and vasoconstriction, to 
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a lesser degree [14]. PAH is a panvasculopathy, mainly affecting the small pulmonary 
resistance arteries, characterized by intimal hyperplasia, medial hypertrophy and 
arteriolar occlusion [14], in some cases with a genetic component [15-18]. 
 The RV is gaining strength in determining the prognosis [19,20] and risk 
stratification [21] of PAH patients, and its response to increased afterload  determines 
the patient outcome [22,23]. The RV hypertrophies and dilates due to increased 
afterload, through elevated PVR, and its adaptive response is irregular amongst 
different patients. Since the neonatal RV adapts much easier to increased afterload, 
paediatric PAH, associated with CHD, has a much higher survival rate than adult-
developed PH [24]. In spite its established  importance in PAH, and the potentially 
reversible RV hypertrophy and failure [25,26], little is known regarding RV dysfunction 
and the effects of current therapies on the RV in PAH [7,27]. 
 RV dysfunction in PAH entails neuroendocrine activation, fibrosis, apoptosis, 
oxidative stress, inflammation and mitochondrial dysfunction [7], and in fact an increase 
afterload on the RV imposed by elevated PVR is not sufficient in the development of 
RVHF [28]. PAH-associated ventricular dysfunction does not come one-sided, besides 
the RV, the LV is also compromised in PH [29], through ventricular interaction and 
unloading of the LV [30-32]. 
 
Current therapies for PAH 
Random clinical trials over the past few decades led to the development of 
several treatment approaches [7]. Currently, accepted treatments for PH comprise 
calcium channel blockers (CCBs), prostanoids, endothelin receptor antagonists (ERAs) 
and phosphodiesterase type-5 inhibitors (PDEis) [8]. 
 In the 1980s the focus of PPH treatment was vasodilator drugs [33], which 
lacked studies regarding their long-term effects. This led to an increased attention 
being given to high CCBs. However, only a few patients with iPAH responded to 
therapy with high dosages of CCBs [34]. Due to its negative inotropic effects and 
systemic vasodilation [35], CCB therapy started being used only when an acute 
vasodilator test came out positive [36] leading to a decrease in mean pulmonary artery 
pressure ≥ 10 mmHg reaching a level below 40 mmHg, with a stable or increased 
cardiac output and sustained systemic pressures [8]. 
Once  vasodilatory and anti-platelet aggregating properties [37] are essential for 
protection against PH-associated injury [38,39], prostanoids also received interest in 
the treatment of PH ,. PH patients present decreased pulmonary arteries levels of 
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prostacyclin synthase [40], as well as urinary levels of prostacyclin metabolites [41], 
giving a possible explanation for pulmonary vasoconstriction, smooth muscle cell 
proliferation and increased coagulation [42]. Human trials have demonstrated that 
prostacyclin treatment resulted in several positive outcomes in patients with PAH [43-
49], leading to the approved treatment of PAH with epoprostenol, treprostinil, iloprost 
and beraprost [7]. 
Clinical trials have led to the approval of ERAs as treatment for PAH. A non-
selective ERA, bosentan led to, in a small cohort study, hemodynamic improvements 
[50], which persisted in a 1 year follow-up [51]. Larger cohorts also demonstrated 
improved its efficacy in improving hemodynamic deterioration associated with PAH 
[52,53]. Despite the beneficial effects of orally-administered bosentan [54], hepatic 
function deterioration and anemia might occur during treatment [14]. A selective 
endothelin receptor type A ERA, ambrisentan, has also been approved for the 
treatment of PAH [55]. Sitaxentan, which has also shown bosentan-like improvements, 
revealed secondary effects that might induce liver failure [56], leading to its withdrawal 
from the market [57]. Another non-selective ERA, tezosentan has been getting some 
attention, specifically in animal models of PAH, where its application resulted in acute 
attenuation of PAH [58], through improved pulmonary artery pressure and survival 
[59,60], as well as improved overall hemodynamics and attenuated neuroendocrine 
activation [61]. Regardless its positive outcomes, and planned clinical trials 
(NCT01077297), no data is yet available regarding its use in PAH patients. 
Nitric oxide (NO), as a selective pulmonary vasodilator, is widely used for the 
determination of vasoreactivity in patients with PAH [62], and acute treatment of 
respiratory failure and PH [63]. Cyclic guanosine monophosphate (cGMP) is generated 
in response to NO, and is degraded by phosphodiesterases (PDE). The usage of 
PDEis present beneficial effects in PAH. The first used PDEi, sildenafil, improves PH 
outcome [64,65], showing decreased mean pulmonary artery pressure and PVR [66]. 
As for sildenafil, another PDEi has been approved for the treatment of PAH, tadalafil 
[67] 
Despite its clear usefulness, possibility of combining different class drugs in a 
combined therapy [68-70] and promise in preventing the onset of PH, all available 
therapies only alleviate the symptoms and slow down deterioration, leading to the 
necessity of invasive procedures, such as lung or lung-heart transplantation, in severe 
and more advanced cases. Therefore, new strategies for the cure and treatment of PH 
are needed [71]. 
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Experimental PAH 
Several animal models have been used to simulate PH [72]. The chronic 
hypoxia and monocrotaline injury models are the most commonly used, and regardless 
the controversial attitude towards the agreement that they do not represent human 
PAH, they have allowed for a better understanding of PAH and development of novel 
therapies. 
The monocrotaline (MCT)-induced PAH relies on the toxic pyrrolizidine alkaloid 
present in the plant Crotalaria spectabilis, whose ingestion was described to result in 
progressive development of PH [73]. Upon ingestion, MCT is metabolized in the liver to 
form a reactive bifunctional cross-linking compound which leads to vascular injury [72]. 
Its requirement of hepatic metabolization, by cytochrome P-450 leads to an increased 
variability between animals of the same species and strain. The mainly used model is 
the rat, although other animal models might be exploited [74,75].  
The mechanisms through which MCT induces PAH are not fully understood 
[72], although several studies have determined possible explanations for its 
pathological action. Muscularization of small sized pulmonary arteries and right 
ventricular hypertrophy secondary to that [76]. Vascular morphological changes are 
preceded by adventitial inflammation, involving first intraacinar arteries and,later on, 
major bronchus associated arteries and the involvement of both arteries and veins [77], 
which might be regulated by adventitial fibroblasts [78]. Failure of the pulmonary 
vascular endothelium to repair, through MCT pyrrole-mediated DNA cross-linking [79] 
might also be underlined on the development of MCT-induced PH. Extracellular matrix 
alterations are also associated with MCT injury, both at the arterial lumen and at the 
medial-adventitial border [80]. A more recent study has described that, pulmonary 
endothelial cells, in response to MCT, present megalocytosis [81], which might 
contribute to lumen obliteration. These changes in the vascular bed could be the cause 
for RV modifications, specifically hypertrophy, which might be associated to an 
imbalance in endothelin-1 synthesis in the pulmonary arteries, contributing to the 
progression of cardiopulmonary alterations in MCT-induced PAH [82]. 
In spite of its possible limitations [83], the MCT-induced PAH model has allowed 
for the development of the most relevant therapeutic approaches to PAH [72], 
specifically prostanoids and prostacyclin receptor analogs [84-86], ERAs [87-91] and 
PDEi [92-96]. 
Recently, a great deal of attention has been given to neuregulin-1 (NRG-1) and 
its effects in the development and maintenance of the cardiovascular system. This has 
opened the way for several research groups to determine its effects in treating several 
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cardiovascular pathologies and to determine the mechanisms through which its 
cardioprotective action is achieved. Ultimately, this led to clinical trials being approved 
and the observation that patients with chronic HF treated with NRG-1 showed improved 
cardiovascular function [97].  
To this regard, we believe it might be also implicated in the development and 
possible treatment of PAH, and therefore, in the next sections of this thesis, we will 
describe the current knowledge regarding NRG-1 and its possible applications in the 
treatment of cardiovascular diseases. 
 
Neuregulins and their receptors  
Neuregulins are a large family of proteins that are mainly present in the nervous 
system, heart, mammary glands, intestine and kidneys [98]. It is composed of several 
members, neuregulins 1 to 4 (NRG-1 to 4). NRG-1s were the first to be described. Nrg-
1 differently transcribed gives rise to three different isoforms, types I to III (Figure 1). 
These isoforms are classified according to their type specific N-terminal sequence. 
Type III has a cysteine-rich domain which makes it a transmembrane protein [99]. The 
EGF-like domain can also form different isoforms, isoform α or β which result from 
alternative splicing.  
Several names have been appointed to the different NRG-1 isoforms: heregulin, 
Neu differentiating factor (NDF), glial growth factor (GGF I-III), acetylcholine receptor 
inducing activity (ARIA) and sensory and motor neuron-derived factor (SMDF) [99], and 
although being the first descriptions in the literature, they do not correlate with each 
isoforms main biological activity in vivo [100].. Functionally, NRG-1 has been the most 
studied so far. Within the NRG family only NRG-1 has been associated with 
cardiovascular development and diseased states [98] and thus will be the focus of this 
review. 
NRG-1 proteolytic activation results from the activity of specific proteases, 
namely beta-secretase 1, a-disintegrin and metalloproteinase (ADAM)  domain-
containing protein 10, which have different cleavage sites, resulting in different 
functionally active soluble forms of NRG-1 [101].Both isoforms characteristics and 
synthesis as transmembrane proteins or non-membrane proteins define their function 
and biological activity [100]. 
NRG-1 mRNA expression and protein synthesis is mediated by neurohormones 
(inhibited by angiotensin II and phenylephrine and induced by endothelin-1), as well as 
by mechanical strain (which increases NRG-1 expression) [102].  
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NRGs bind specifically to ErbB receptors, ErbB3 and ErbB4 (also known as 
HER3 and HER4). Ligand binding activates the specific monomeric receptor and leads 
to its dimerization. Receptor dimerization results in homodimers or heterodimers which 
when activated trigger both the mitogen-activated protein kinase (MAPK) and the 
phosphatidylinositol-3-OH kinase (PI(3)K)/Akt pathways (Figure 2). The activation of 
this axis is regulated by the combination of receptor dimers and ligand and results in 
the activation of cell-survival, migration, proliferation, adhesion and differentiation 
related pathways [100,103]. NRG-1 acts mainly in the nervous system, through ErbB3 
receptor and in the heart through ErbB4 receptor activation. 
 
 
Figure 1 – NRG-1 synthesis and proteolytic activation. NRG-1 can be synthesized either as a soluble form or as a 
transmembrane form. Types I and II are synthesized as membrane proteins, but upon cleavage by proteases are 
released in its soluble form and can act in a paracrine way. Type III is synthesized as a two-fold transmembrane protein 
that upon protease activity is still attached to the membrane, acting in a juxtacrine way. Differences between type I and 
II are accounted for their EGF-like domain, and while types I and II have an Ig-like domain, type III doesn’t. NRG-1 binds 
to ErbB3 or ErbB4 leading to dimerization of the receptors and transphosphorylation of their tyrosine kinase domains 
and activation of MEK/MAPK and PI3K/Akt signalling pathways leading to cell growth and survival cascades. ErbB4 is 
the only receptor who can form active homodimers, since ErbB2 is an “orphan” receptor and therefore cannot be bound 
by NRG-1 and ErbB3 has an inactive tyrosine kinase domain. Only ErbB2/ErbB4 and ErbB4/ErbB4 dimers are 
represented, other possible receptor combinations are ErbB2/ErbB3, ErbB3/ErbB4. 
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NRG-1 role in the cardiovascular system 
Besides having a crucial role in cardiac embryonic development and endothelial 
stem cell differentiation, the NRG-1/ErbB signalling cascade has considerable 
physiological and pathophysiological functions in the adult heart.  
In the heart, NRG-1 is expressed in endocardial and microvasculature 
endothelium, ErbB4 and ErbB2 are expressed in cardiomyocytes and ErbB3 is 
expressed in mesenchymal cells of the endocardial cushion [102,104,105]. Ligand and 
receptors differential expression entails the paracrine transduction pathway associated 
with this signalling axis, and the presence of different receptors in different cell types 
determine the different phenotypes observed in differential knock-out models. In fact, in 
vitro studies have confirmed the paracrine way through which NRG-1 acts (specifically, 
myocardial microvasculature endothelium-synthesised NRG-1 acts on adjacent 
cardiomyocytes [102]). 
 
NRG-1 role cardiac embryogenesis and cardiac cell differentiation 
Several processes in heart embryogenesis are dependent of the NRG-1/ErbB 
signalling pathway. Cardiac trabeculation and myocardial development is regulated by 
the NRG-1/ErbB system, which is essential for cardiac muscle differentiation.  
ErbB4 mutant mice present deficient myocardial trabeculae formation in the 
heart ventricle, and die during mid-embryogenesis. The same outcome is present in 
NRG mutants, demonstrating the direct association between ligand and receptor in the 
heart and its importance in cardiac development [104,106]. The gene regulatory 
network required for proper myocardium development is also maintained by this 
system, in large degree mediated by the transmembrane region of the membrane-
anchored NRG-1 [107]. 
NRGs receptor and co-receptor ErbB3 and ErbB2, respectively, are also 
important in cardiac development. Heterozygous mice, with a null ErbB2 allele die at an 
embryonic stage, possibly due to cardiac trabeculae dysfunction [108] and mutant mice 
lacking the ErbB3 gene present a thinner ventricular wall, and malformation of the 
cardiac cushion which leads to poor valvulogenesis, resulting in embryo death, as 
shown for NRG (-/-) and ErbB2 (-/-) mice [109]. 
Proteolytic activation is also mediated by the intracellular portion, whose mutant 
impairs ErbB receptor activation [110]. 
By treating atrioventricular canal explants from mutant (Has2 -/-) mice embryos, 
which show deficient mesenchymal cell formation, essential for heart valve 
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development, with NRG-1, a normal phenotype was observed, through phosphorylation 
of ErbB2 and ErbB3 receptors [111]. 
Altogether, these studies point to the essential role of NRG-1 signalling in heart 
embryogenesis.NRG-1 plays a crucial role in cell differentiation in the heart. Depending 
on the cell type and on the developmental window, it can both lead to the differentiation 
of cardiac conduction system cells [112], and working type cardiomyocytes [113] . 
NRG-1 treatment induces the differentiation of embryonic cardiomyocytes into 
cardiac conduction system cells, both in cultured cardiomyocytes and in whole 
embryos [112]. On the other hand, differentiation of stem cells into working type 
cardiomyocytes is also regulated by NRG-1 [114]. Exogenous administration of NRG-1 
further increases the expression of working-type related genes [113]. Conversely, 
inhibiting NRG-1/ErbB signalling promotes nodal cardiomyocyte formation [113]. 
 
NRG-1/ErbB signalling in cardiac cellular responses 
Cardiac myocyte apoptosis in response to oxidative stress is regulated by NRG-1. 
Inhibiting NRG-1/ErbB signalling results in increased cardiomyocyte death, and treating 
cells with exogenous recombinant NRG-1 promotes cell survival [115]. In the absence 
of exogenous NRG-1, ErbB4 activation and cellular protection is dependent on the 
cardiac microvascular endothelial (CMVE)-derived NRG-1β [115]. Cell survival in this 
context is PI3K/Akt dependent through suppression of mitochondrial cytochrome c 
release and caspase-3 activation [116,117] Furthermore, inhibition of ErbB receptors (4 
and 2) leads to induction of Bcl-x splicing towards its pro-apoptotic protein Bcl-xS, 
leading to mitochondrial dysfunction and apoptosis [118]. Treatment of adult rat 
ventricular myocyte cultures with NRG-1 resulted in increased proliferation [119], 
through ErbB4 signalling. Myocyte hypertrophy was also observed, shown by 
increased protein synthesis and prepro-atrial natriuretic factor upregulation, dependent 
on the p70S6- and MAPK-kinases [120]. CMVE exerted a cardiomyocyte hypertrophic 
response, which was abolished by ErbB2 inhibition [102].  
 
NRG-1/ErbB signalling role in cardiac and vascular functionn 
Recent experimental evidence reveals that NRG-1 regulates myocardial 
performance and sympathovagal balance, suggesting that it dynamically participates in 
hemodynamic homeostasis of the cardiovascular system. 
NRG-1 induces a negative inotropic effect, which is preserved during 
adrenergic stimulation with isoproterenol, providing a counterbalance over the 
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autonomic imbalance present in heart failure [121]. The negative inotropic effect is 
dependent on nitric oxide production, through NRG-1 activation of Akt and subsequent 
eNOS phosphorilation [121].Both eNOS and β-adrenoreceptors are translocated to the 
caveolae, where eNOS attenuates adrenergic stimulation while increasing excitation-
contraction coupling. Interestingly, ErbB receptors are also co-localized with eNOS in 
the caveolae [122], allowing for a better spatial relation between NRG-1 activation of 
ErbB receptors, and downstream signalling leading to its NO-mediated, anti-adrenergic 
cardioprotective effects. 
Additionally, cardioprotection exerted by parasympathetic muscarinic receptors 
activation over excessive β-adrenergic stimulation, characteristic of heart failure, is 
abolished in ventricular myocytes from heterozygous (NRG-1+/-) mice [123].  
Treatment of cardiomyocytes with NRG-1 results in increased cytosolic calcium 
uptake. Phospholamban is increasingly phosphorylated, in a PI3K and PKG dependent 
manner, revealing an additional protective role of NRG-1, specifically in diastolic 
calcium handling [124]. 
Antagonising ErbB2 while treating cells with a mitotic inhibitor, used in cancer 
therapy, increases cardiac tissue myofibrilar structural and functional depletion, further 
confirming the critical role that the ErbB2 receptor plays in protecting the heart from 
stress induced by chemotherapeutic agents [125]. 
Growing evidences support a role for NRG-1 in vascular function and structure 
with clear implications for cardiovascular biology. 
NRG-1 is expressed in vascular endothelial cells [126], and its receptors are 
localized to the underlying smooth muscle cells.  
NRG-1 proved to be angiogenic in in vitro (collagen gel tube formation) and in vivo (rat 
corneal angiogenesis and chick embryo chorioallantoic membrane) models [127,128]. 
Undoubtedly, NRG-1’s role in angiogenesis is clear, not only in normal 
physiological conditions, but also in response to tissue damage. In ischemic injury 
NRG-1 is required for proper angiogenesis and arteriogenesis [129]. Additionally, NRG-
1 is expressed in atherosclerotic lesions [130] and associated  with the inhibition of 
neointimal formation and of mitogen-induced vascular smooth muscle cells proliferation 
and migration after vascular injury [131]. These studies suggest that NRG-1 may be a 
novel therapeutic candidate for the prevention of neointimal formation in diseases, such 
as atherosclerosis and restenosis. 
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NRG-1/ErbB signalling alteration in cardiovascular disease 
Together with the premature development of dilated cardiomyopathy in NRG-
1/ErbB–deficient mice [132-134], animal studies have demonstrated important changes 
within the cardiac NRG-1/ErbB system during the progression of heart disease.  
NRG-1 mRNA and protein levels, as well as ErbB4 receptor phosphorylation, 
are increased in response to ischemic damage [135]. Moreover, deleting the NRG-1 
gene in endothelial cells causes the abolishment of their cardioprotective role in these 
conditions. Both at the cell culture and at the whole heart level, endothelial cell-derived 
NRG-1 has a major  protective role against apoptosis and functional impairment during 
hypoxia/reoxygenation – ischemia/reperfusion, through ErbB4 [136] and eNOS 
activation [137]. 
Several studies show that impaired NRG-1 signalling exacerbates the 
doxorubicin(Dox)-mediated cardiac toxicity. NRG-1, as well as Erbb4 receptor 
knockouts show increased susceptibility to Dox-treatment [138,139] and Dox-
associated cardiomyocyte myofilament injury is increased when NRG-1’s co-receptor, 
ErbB2, is inactivated [140]. Indeed, ErbB2 inhibition and consequent ERK-1 absent 
phosphorylation is sufficient to abolish CMVE and exogenous NRG-1 protection 
against anthracycline-induced apoptosis [102]. Moreover, NRG-1 protects against Dox-
induced SERCA dysfunction and calcium uptake deficiency through Akt activation 
[141]. 
NRG1/ErbB pathway is also impaired in diabetic cardiomyopathy (DCM). Type 
2 diabetes in mice leads to deficient ErbB receptor activation in the left ventricle and to 
delayed cardiac muscle relaxation. Chronic treatment with NRG-1, but not with insulin, 
reversed these cardiac muscle disturbances [142]. Consistently, ErbB2 and ErbB4 
receptor expression and phosphorylation as well as NRG-1 protein synthesis are 
decreased in DCM [143].  
In pacing-induced heart failure, although ErbB2 and ErbB4 receptor 
phosphorylation increase concurrent with NRG-1 and ADAM19,  the downstream 
signaling is, at least partly, abrogated, once the downstream mediators of the NRG-
1/ErbB signalling pathway (Akt and ERK1/2) remained inactivated [144].  
In an in vivo model of chronic left ventricular hypertrophy secondary to aortic 
stenosis, both ErbB2 and ErbB4 levels are downregulated when ventricular failure 
begins [145]. NRG-1 levels were increased during the concentric hypertrophic phase, 
which correlates with NRG-1 increased synthesis in response to mechanical strain 
[102]. Upon left ventricular dysfunction and eccentric left ventricular hypertrophy, NRG-
1 levels decreased. These changes are possibly due to the increased neurohumoral 
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activation, mainly mediated by angiotensin II and phenylephrine, during left ventricular 
failure which exert a negative regulation on NRG-1 production [102].  
Collectively, these studies show that in conditions of ventricular damage and 
dysfunction, activation of NRG1/ErbB signaling is part of an adaptive compensatory 
program that preserves function. At more advanced stages of ventricular dysfunction, 
however, activity of the NRG1/ErbB system is attenuated. This maladaptive change is 
the result of reduced ventricular expression of NRG-1, reduced expression of ErbB 
receptors, and dysfunctional downstream ErbB signaling. Attenuation of compensatory 
NRG1/ErbB signaling may thus be an important event in the progression of heart 
failure. 
A graphical representation of NRG-1’s effects is presented in Figure 2. 
 
 
 
Figure 2 – NRG-1 effects on development and pathophysiology of the cardiovascular system. 
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Preclinical Studies 
 
The therapeutic potential of NRG-1 as a potential treatment for heart failure has 
been demonstrated in several animal models models  (Table 2). 
Structural and functional changes associated with myocardial infarction are 
attenuated and improved when treatment with NRG-1 is applied [119,146,147], and this 
effect is dependent on PI3K/Akt activation [135,146,148]. This improvement in function 
is partially related with the cardiomyocyte replacement after ischemic injury [119]. 
Additionally, transfection of myocardial infarct areas with lentivirus carrying an 
overexpressed NRG-1 gene, resulted in improved cardiac function and prevention of 
apoptosis [149]. 
In Dox-induced cardiomyopathy, treatment with NRG-1 improved cardiac 
function and survival [147,150]. 
Treating DCM-induced rats with NRG-1 resulted in improved ventricular 
function and structure. Left ventricular systolic and diastolic dysfunction associated with 
diabetes were significantly attenuated, as well as apoptosis and fibrosis of the heart 
tissue [151] . 
In in vivo and in vitro myocarditis models, NRG-1 treatment attenuated the 
impairment of cardiac function, as well as, protected against histological and 
biochemical (decreased plasmatic cTnI levels) changes [147]. 
NRG-1 administration produced global improvements in cardiac performance in 
a canine model of pacing-induced heart failure [147]. Additionally, in primates, namely 
rhesus monkeys, with pacing induced heart failure, NRG-1 treatment enhanced 
contractility (through alpha-myosin heavy chain upregulation), and protected against 
apoptotic injury [152].  
Altogether, these results suggest that the NRG-1/ErbB signalling pathway is in 
fact altered in cardiac injury and modulation of this axis results in improved cardiac 
function. 
 
 
 
 
 
 
 
 
 
  
Table 2 – Neuregulin-1 therapeutic effects in animal models of heart failure. 
Ref. Model / species Treatment Outcome 
 [147] MI / rat 10 μg/kg/day IV. for 5 or 10 days 1 week or 2 months after LAD ligation 
Improved LV structure and function, decreased neurohumoral activation and 
improved survival. 
 [119] MI/mouse 2.5 ug/mouse IP for 12 weeks 1 week after LAD Improved structure and function 
 [135] MI – I/R /rat 1, 2, 4 or 8 μg/kg IV for 20 minutes prior to I/R 
Improved structure, decreased release of ischemia-injury markers and decreased 
apoptosis 
 [148] MI/ rat 5 μg/kg/h IV for 7 days, 8 weeks after LAD ligation Improved structure and function through MLC upregulation 
 [146] MI /rat 10 μg/kg/d IV for 10 days, 4 weeks after LAD ligation Improved structure and function and attenuation of mitochondrial dysfunction 
 [149] MI /rat Injection of infarcted area with rhNRG-1 carrying lentivirus 
Decreased apoptosis and increased revascularization through increased Akt and 
eNOS activation 
 [147] Dox-induced CM / rat 20 μg/kg/day IV for 5 days 4 weeks after first doxorubicin administration 
Improved function and survival, and decreased necrosis  
 
 [150] Dox-induced CM 
0.75 mg/kg/day SC for 3-5 days (beginning 1 day prior to doxorubicin 
administration) 
Improved function and survival, decreased myocardial injury markers and increased 
Akt phosphorylation 
 [153] DCM / rat Inhibitory anti-ErbB4 30 μg, IV 3 times per week for 4 weeks 
Decreased NRG-1/ErbB signaling and pro-inflammatory gene expression, while no 
changes in LV function 
 [151] DCM / rat 
10 μg/kg, IV every 2 days, for 2 weeks, 12 weeks after streptozotocin 
injection 
Improved LV function and decreased apoptosis and fibrosis 
 [147] Myocarditis / mouse 30 μg/kg/day IV for 5 days  
Improved LV structure and function and survival, and decreased myocardial 
necrosis 
 [147] CRP / beagle dog 
3 μg/kg/day IV for 5 days with continuous pacing, 3 weeks after after the 
beginning of rapid pacing 
Improved function 
 [152] CRP / rhesus monkey 3 μg/kg/day IV for 10 days Improved function and increasedα MHC expression 
Akt – protein kinase B; CM – cardiomyopathy; CRP – chronic rapid pacing; DCM – diabetic cardiomyopathy; Dox – doxorubicin; eNOS – endothelial nitric oxide synthase; IP – intraperiotneal IV – 
intravenous; I/R – isquemia/reperfusion; LAD – left anterior descending artery; LV – left ventricular; MI – myocardial infarction; MHC – myosin heavy chain; MLC – myosin light chain; SC – 
subcutaneous.   
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Human studies 
Since the observation that patients undergoing clinical trials for cancer 
treatment with trastuzumab, an antagonist of the ErbB2 receptor, developed an 
increased risk of cardiac dysfunction, huge attention was given to the NRG-1/ErbB 
pathway in the heart [154]. Animal research has demonstrated the importance of the 
NRG-1/ErbB pathway in cardiac development and its pathophysiology, leading to 
several experimental studies that tried to characterize its function and determine its role 
in human cardiovascular function.  
Several “bench” studies have taken the data gathered so far and with human 
samples have tried to describe through which mechanisms NRG-1 is involved in 
human cardiovascular disease.  
In ventricular tissue from patients with advanced heart failure, increased NRG-1 
and decreased ErbB2/ErbB4 mRNA expression have been observed. Interestingly, in 
patients who had left ventricular unloading with ventricular assist devices, the changes 
reversed [155].  
Quantification of serum NRG-1 levels, in a cohort of 899 patients with chronic 
heart failure, showed that increased NRG-1 levels were associated with increased 
disease severity (I-IV class of the New York Heart Association - NYHA) and risk of 
death or cardiac transplantation. This study identifies NRG-1 as a novel biomarker of 
heart failure, presenting a higher correlation together with brain natriuretic peptide than 
each biomarker individually [156]. 
Patients with coronary artery disease, namely acute coronary syndrome and 
effort angina pectoris presented lower plasmatic levels of NRG-1 than patients with 
mild hypertension or healthy subjects. The lowest levels of NRG-1 detected in acute 
coronary syndrome patients inversely correlated with the severity of lesions. In 
addition, NRG-1 expression (by macrophage foam cells) was found to be directly 
correlated with the progression of the atherosclerotic plaque [157].  Another group 
demonstrated that both serum and plasma NRG-1 levels inversely correlated with 
severity of coronary artery disease. In this study plasma NRG-1levels were two-fold 
higher than serum and were higher in patients with stress-induced ischemia [158].  
Perik et al [159] in a cohort of 50 heart failure patients found that serum ErbB2 was 
increased in patients with higher NYHA classes, lower left ventricular ejection fraction 
and higher apoptotic-related cytokines. However, a larger cohort of 765 showed that 
plasmatic levels of ErbB2 were not associated with left ventricular end-diastolic 
pressure or ejection fraction, in spite myocardial tissue deregulation of HER2 
expression [160]. 
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Clinical trials 
Recent clinical trials have demonstrated the effects of the therapeutic 
administration of recombinant human NRG-1 (rhNRG-1) in patients with stable chronic 
heart failure on optimal medical therapy [161,162] (Table 3).  
A phase II trial, in which a daily intravenous infusion of rhNRG-1was given to 
patients during 10 consecutive days, showed an increase in left ventricular function and 
structure observed at day 30 after the 10-day treatment. On day 90, structure and 
function were even further increased [161].  
Another phase II trial in which patients received a consecutive 12 hour 
intravenous infusion of rhNRG-1 during 10 days showed an increase in cardiac output 
of 30% and a decrease in pulmonary artery wedge pressure and systemic vascular 
resistance of 30 and 20%, respectively. Twelve weeks following the 11 days infusion 
left ventricular ejection fraction suffered a 12% increase [162]. 
 Importantly, in these studies, the short-term rhNRG-1 administration was safe and well 
tolerated. 
Larger trials are now on-going. A phase IIa interventional clinical trial, has set to 
determine, over a period of 12 months, the efficacy and safety of NRG-1 as a treatment 
in 120 patients with chronic heart failure( NCT01251406), and the same group also 
planned a phase III clinical trial with the purpose of evaluating the efficacy of NRG-1 in 
reducing death rate of this condition( NCT01541202). 
 
  
 
Table 3 – rhNRG-1 clinical trials 
Ref Description Patients Dosage End-Points Outcomes 
 [161] 
Phase II, randomized, 
double-blind, multicenter, 
background therapy-
based, placebo-controlled, 
parallel group study 
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0.3, 0.6 or 1.2 μg/kg 
10-h IV infusion for 
10 consecutive days 
 
Change in LVEF%, ESV or EDV as measured by 
MRI at baseline and days 11, 30 and 90 
Cardiac function classification (NYHA); 
6-min walk test; 
QOLS; 
Plasma NT-proBNP. 
 
Improved and sustained LVEF% and decreased LVEDV and LVESV 
at 30 and 90 days after treatment compared with baseline (no 
differences between the treated and placebo group) 
 
 [162] 
Single-centre, 
prospective, non-
randomized, open label 
study 
15 
Initial dose of 1.2 
μg/kg for 6 h 
0.6, 1.2 or 2.4 μg/kg 
12 hour IV infusion 
for 10 consecutive 
days 
Changes in acute (first 24 h) and sustained after 12 
weeks haemodynamics measured by Swan-Ganz 
catheterization; 
Changes in LVEDV, LVESV and LVEF measured 
by MRI on days 12, 28 and 84; 
Changes in NA, ALD, ET-1, NT-proBNP, PIIINP, 
highly sensitive hsCRP, TNF-α and IL-6. 
 
Acute increase in CO; 
Improvement in LVEF; 
No changes in LVEDV or LVM; 
Decrease of serum NA and aldosterone. 
ALD – aldosterone; CO – cardiac output; EDV – end-diastolic volume; ESV – end-systolic volume; ET-1 – endothelin-1; hsCRP – highly sensitive C-reactive protein; IL-6 – interleukin-6; LVEF – left 
ventricle ejection fraction; LVM – left ventricle mass; MRI – magnetic resonance imaging; NA – noradrenaline; NT-proBNP – n-terminal pro-B-type natriuretic peptide; NYHA – new york heart 
association; PIIINP – procollagen III N-terminal propeptide; QOLS – quality of life score;TNF-α – tumor necrosis factor alpha.
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Purpose 
Animal research data has allowed the determination of several effects and 
subcellular mechanisms through which NRG-1 acts on cardiovascular system, in health 
an disease, leading to several studies in human patients. 
Results from clinical trials have proved that indeed NRG-1 is a modulator of 
cardiovascular function, showing improvements in several hemodynamic parameters in 
patients with chronic heart failure, both acutely and in a long time period manner, 
underlying its important role in the cardiovascular system and its potential usage as a 
HF therapeutic agent. 
Following the notion that NRG-1/ErbB signaling has protective effects on the 
myocardium and vasculature, the question arises whether pharmacological NRG-
1/ErbB activation has any preventive or curative potential in PAH and RV heart failure..  
Taking into account that  RV failure is the most severe complication of PAH, 
and NRG-1’s effect in improving cardiac function and structure in several animal 
models, leads us to assume that NRG-1 might result in an attenuation of RV 
deterioration in PAH.  
The structural changes seen in the pulmonary vessels in PAH include medial 
thickening (due to smooth muscle cell hyperplasia and hypertrophy), formation of a 
neointimal composed of smooth muscle cells or myofibroblasts embedded in a 
mucopolysaccharide matrix and the occurrence of plexiform lesions (due to endothelial 
and smooth muscle cell proliferation). To date, there are no studies concerning the 
effect of NRG-1/ErbB system in pulmonary vasculature, but we know that NRG-1 is 
synthesised by the endothelium, its receptors are expressed in the underlying smooth 
muscle cells, and additionally, that NRG-1 attenuates neointimal formation following 
vascular injury, and inhibits the proliferation of vascular smooth muscle cells in other 
vascular beds (7), facts that emphasize the need of experimental studies in order to 
determine the role of NRG-1/ErbB system in PAH context. 
One of the most successful therapeutic approaches to PAH has been ET-1 
blockade through bosentan, an orally active nonselective ET receptor antagonist, 
approved by the Food and Drug Administration. Recently, ET-1 involvement in the LV 
dysfunction that accompanies longstanding severe PAH, has been shown [163]. 
Moreover, it is also known that endothelial NRG-1 synthesis is stimulated by ET-1 
[102]. On the other hand, there is experimental evidence showing the existence of an 
inhibitory cross-talk between ET and ErbB receptors in the adult heart [164]. These 
facts reinforce once more the pertinence of the present study, having into account the 
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relevance of the ET-1 system for the pathophysiology of PAH and RV HF and its 
interaction with the NRG-1 system. 
 We therefore believe that NRG-1 might play a pivot role in the pathophysiology 
and treatment of PAH and PAH-associated RV hypertrophy and failure. To this point 
we set out to determine the effects of rhNRG-1 chronic treatment in an animal model of 
MCT-induced PAH. 
Based on the actual knowledge described in the previous sections, we 
hypothesize that activating the NRG-1 system in PAH animals might protect not only 
lung vessels, but also the RV and LV myocardium and thus increase animal survival, 
attenuate PAH and improve RV and LV myocardial function. Therefore, this work 
aimed to investigate the role of the NRG-1/ErbB system in the pathophysiology PAH 
and in the progression to HF and, thus, to contribute for the development of new 
therapeutic approaches. 
Our specific goals are: (i) to determine changes in the expression of NRG-1 in 
the heart tissue from healthy rats and from rats with PAH induced by MCT; (ii)to assess 
changes in RV and LV myocardial function and the severity of PAH, in vivo 
(hemodynamic and echocardiographic studies) and in vitro (isolated cardiomyocytes 
and pulmonary vascular muscle studies); (iii) to analyze myocardial and pulmonary 
structure and histology, and their patterns of gene expression in healthy animals and in 
animals with PAH with or without short-term NRG-1 treatment. 
The work plan was executed in the context of the funded project "Role of the 
neuregulin system in pulmonary arterial hypertension - pathophysiological and 
therapeutic implications" (ref.PTDC/SAU-FCF/100442/2008). 
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METHODS 
All the procedures in this work followed the recommendations of the Guide for 
the Care and Use of Laboratory Animals, published by the US National Institutes of 
Health (NIH Publication No. 85-23, Revised 1996), and are accredited by the 
Portuguese Direção Geral de Veterinária (DGV) and approved by Fundação para a 
Ciência e a Tecnologia (FCT PTDC/SAU-FCT/100442/2008). 
Animal model 
Seven week-old male Wistar rats (Charles River Laboratories, Barcelona, 
Spain) weighing 180–200g, were randomly assigned to receive either a subcutaneous 
injection of 60mg/kg monocrotaline (MCT, Sigma Chemical) or an equal volume of 
vehicle (saline). Fourteen days after MCT/vehicle administration, animals were 
randomly assigned into 4 subgroups: (i) untreated animals (CTRL); (ii) animals with 
induced PAH and without pharmacological treatment (MCT); (iii) animals with induced 
PAH and with pharmacological treatment (MCT + rhNRG-1); (iv) animals without PAH 
and with pharmacological treatment (CTRL + rhNRG-1). Pharmacological treatment 
consisted on a daily intraperitoneal administration of 40μg/kg of rhNRG-1 (Peprotech, 
Offenbach, Germany) during 7 days, while the vehicle treatment consisted in Bovine 
Serum Albumin (BSA, Sigma-Aldrich, 0.1% during 7 days). A separate group was 
created, where MCT animals received a 250mg/kg/d gavage of bosentan (25mg/mL in 
5% gum Arabic, starting 2 days after MCT or vehicle,  kindly provided by Actelion 
Pharmaceuticals).The drug dosages, administration routes, and treatments duration 
were selected on the basis of previous studies from our and others research teams 
[119,147,163,165] or of preliminary dose-finding studies (unpublished data).  
Animals were grouped 5 per box, in a controlled environment, with a light-
darkness cycle of 12:12h, controlled temperature at 22ºC, and water and food ad 
libitum. Before MCT administration, an echocardiographic evaluation was performed, in 
order to allow a basal evaluation to compare experimental groups and also as a 
guarantee that the potentially ill animals (with cardiac disease or other) did not follow 
the protocol. Between 21 and 24 days after MCT administration, the animals were 
submitted again to an echocardiographic evaluation and to invasive hemodynamic 
evaluation. After invasive heamodynamic evaluation, samples were collected and 
processed for in vitro functional studies in cardiomyocytes and pulmonary arteries, as 
well as for morphometric, histologic and molecular biology studies.  
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Echocardiography studies 
Echocardiographic studies were performed one day before the administration of 
MCT (or vehicle) and 21 to 24 days after MCT (or vehicle) injection. 
Animals were anesthetized by an intraperitoneal injection of ketamine/xylazine 
(75mg/kg and 10mg/kg, respectively), placed in left lateral decubitus and the skin was 
shaved. After applying warm echocardiography gel, a 12MHz sensorial probe (GE 
Healthcare) was gently placed on the thorax. 
Acquisitions (General Electrics Vivid 7 echocardiograph, GE Healthcare) were 
averaged from three consecutive heartbeats. Bi-dimensional and M-mode images were 
obtained, in short axis of LV at the papillary muscle level. End-systolic and end-
diastolic LV diameter and wall size were evaluated. In apical projection of 4 and 5 
cavities, after previous acquisition of bi-dimensional image, tricuspid valve flow and 
pulmonary valve flow, were evaluated by conventional Doppler. Right atria area was 
evaluated in the 4 chamber view and tricuspid annular plane systolic excursion in M-
mode following alignment of the gate to the tricuspid valve. 
 
Invasive haemodynamic evaluation 
As previously described [166], 21 to 24 days after MCT administration, 
anesthesia was induced by an intraperitoneal injection of fentanyl and midazolam (100 
μg/kg and 5 mg/kg, respectively) and inhalation of 8% sevoflurane (Penlon Sigma 
Delta). Endotracheal intubation was performed using a 14 gauge catheter and 
mechanical ventilation controlled by a rodent ventilator (MouseVent G500, Kent 
Scientific, Connecticut, USA). Anesthesia was maintained with sevofluorane (2.5-3.0% 
vol/vol). The internal femoral vein was catheterized (24G) under surgical 
microdissection (Wilde M651, Leica microsystems, Cambridge, UK) for infusion (Multi-
Phaser, NE-100, New Era Pump Systems) of warm lactate Ringer’s solution at a rate of 
8 mL/Kg/h. Animals were placed in right-lateral decubitus and after tricotomy, a left 
thoracotomy was performed. Pericardium and pleura were carefully dissected, and the 
phrenic nerve was severed. A 3-0 surgical silk was passed around the inferior vena 
cava (IVC) for transient occlusion during the protocol, and pressure-volume catheters 
were inserted through the apex of RV and positioned along the long axis (PVR-1045, 
1F, Millar Instruments). A flow probe was implanted around the ascending aorta 
(MA2.5PSB, 2.5mm, Precision S-Series, Transonic Systems). The experimental 
preparation was allowed to stabilize for 15 minutes. Baseline and IVC occlusions 
recordings were obtained with ventilation suspended at end-expiration. Pressure and 
volume signals were continuously acquired (MVPS 300, Millar instruments), digitally 
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recorded at a sampling rate of 1000Hz (ML880 PowerLab 16/30, ADinstruments), and 
analyzed off-line (PVAN 3.5 Millar Instruments). Parallel conductance for the volume 
catheter was computed (PVAN) after bolus injection of 50μL hypertonic saline (10%), 
calibration for factor alpha (field inhomogeneity) was determined through the cardiac 
output calculated through the aortic flow probe and the ultrasonic transit time volume 
flowmeter (TS420, transit-time perivascular flowmeter, Transonic systems).  
Following an intravenous 100 mg/kg pentobarbital injection, animals were 
exsanguinated and heparinized blood was collected and used for volume calibration 
with standard cuvettes (P/N 910-1048, Millar Instruments).  
Samples of RV and lung tissue were collected and snap frozen in liquid nitrogen 
and stored at -80ºC. For mRNA quantification, samples were submerged in RNA 
stabilization reagent (RNAlater, Qiagen, 76106, Crawley, UK) and for histological 
analysis samples were stored in buffered 10% formaldehyde. 
 
In vitro studies in isolated skinned cardiomyocytes 
Frozen VD tissue samples were collected in a Petri dish filled with relax solution 
(5.89 mM Na2ATP, 6.48 mM MgCl2, 40.76 mM Propionic acid, 100 mM BES, 6.97 mM 
EGTA and 14.5 mM Creatinine phosphate) and were cut in small pieces. Tissue was 
then pottered to 2.5 mL of relax solution and submitted 3 times to mechanical 
homogenization for 3 seconds at 30 rpm (High Speed 4000 rpm homogenizer, Glas-
Col, Terre Haute, Indiana, USA). Fresh relax solution (2.5 mL) and 0.5 mL of Triton 
10% were added, making a final volume of 5.5 mL. The previous procedures were 
performed on ice. Solution was then left at room temperature for 5 minutes, in order to 
allow Triton to permeabilize cells and dissolve cardiomyocytes’ membranes. 
Homogenate was washed 5 times with relax solution in spin-down cycles of 1 minute, 
1500rpm, and 4ºC (between each wash, lid was removed and a new one was added to 
prevent Triton contamination). 
After isolation, cells were placed under the inverted microscope (IX51 inverted 
microscope, Olympus) and one single cardiomyocyte was attached to the transducer 
and motor tips (1600A – Permeabilized Myocyte Test System, Aurora Scientific), with 
the help of commercial silicone, at a temperature of 20ºC. After 25 minutes to allow a 
proper attachment of the cell to the setup (Model 803B Permeabilized Myocyte Test 
Aparatus, Aurora Scientific), the tests were performed.Cell length was adjusted 
between 2.0 and 2.3 µm and recorded by the motor (315C High-Speed Length 
Controller, Aurora Scientific), which was controlled via computer using custom-
designed software (Series 600A Digital Controller, Aurora Scientific). For offline 
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analysis, force development was also recorded by computer (Series 400A Force 
Transducer Systems, Aurora Scientific). The developed force was measured during 
each activating cycle, being the zero force level identified by instituting a quick ramp 
shortening in cell length, just before moving the cell back to relaxing solution. Force 
development was measured by varying submaximal free-Ca2+ concentrations (using a 
stock solution of 5.97 mM Na2ATP, 6.28 mM MgCl2, 40.64 propionic acid, 100 mM 
BES, 7 mM CaEGTA and 14.5 mM creatinine phosphate) in between the test 
contractions, and corrected for rundown by assuming that each contraction between 
the test contractions at maximum activation contributes equally to the force rundown. 
The pCa ranged from 9.0 (relax solution) to 4.5 (maximal activation) (to the 
proportion of the several Ca2+ solutions. Maximal activation was used in the 
calculation of maximal Ca2+-activated isometric force (Fmax), and the exposure to 
solutions with intermediates pCa yielded the force-pCa relation, normalized for cross-
sectional area. Once a steady-state force level was reached, the cell was shortened 
within 1ms to 80% of the original length (slack test) and after 20ms the cell was re-
stretched and returned to the relaxing solution, in which another slack test (duration of 
10 seconds) was performed. 
Active tension is given as the difference between total tension, measured by 
slacking the preparation during the steady activation (distance between the baseline of 
the force transducer and the steady-force level), and passive tension, measured by 
slackening the relaxed preparation. 
Cells were not included in final analysis if force declined more than 20% 
between the second and the last test contraction at maximum activation [167]. 
 
In vitro studies in vascular preparations 
Following previously described methodology [168], 21 to 24 days after 
MCT/vehicle injection animals were euthanized with 100 mg/kg sodium pentobarbital 
(Eutasil, CEVA). Lungs and heart were excised en bloc and the left upper lobe was 
used to carefully isolate 2nd generation pulmonary artery (200 – 400 μm diameter) 
under the stereo microscope (Stemi 2000C Stereo Microscope, Zeiss). Arterial rings 
were isolated (2 ± 0.2 mm) and mounted between two metallic pins in a horizontal bath 
myograph system (DMT Myograph 720 MO, ADInstruments). Throughout the isolation 
and protocol, the tissue was submerged in modified Krebs-Ringer solution (130 mM 
NaCl, 4.7 KCl, 1.18 mM KH2PO4, 1.17 mM MgSO4, 14.9 mM NaHCO3, 5.5 mM 
glucose, 0.026 mM EDTA and 1.6 mM CaCl2), at a constant temperature of 37ºC, 95% 
O2/5% CO2 and pH 7.4. After a stabilization period, a length-tension curve was 
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obtained through progressive stretching of the arterial rings (20% increase intervals) 
until the target transmural pressure was achieved (target transmural pressure was 
obtained through right heart catheterization as previously described). The preparations 
were allowed to stabilize at target transmural pressure and stimulated with 80 mM KCl 
solution to determine maximum tension development. Three to four solution changes 
followed in order to relax the arterial rings and endothelial function was evaluated 
through a dose-response curve to acetylcholine (10-9 to 10-5 M, in 0.5 logarithmic units 
intervals) performed on pre-contracted rings (10-5 M phenylephrine). Analysis was 
performed offline using appropriate software (LabChart 7 Pro, ADInstruments). 
Histological and morphometric studies 
Immediately after exsanguination of the anesthetized/instrumented animal, 
heart and lungs were excised and weighted [169]. RV and LV + septum were carefully 
dissected and weighted separately. Tissue weight was normalized to animal 
bodyweight. Heart failure is associated with cachexia [166,170] and therefore, 
normalizing tissue weights of MCT-injected animals might lead to an overestimate of 
cardiac hypertrophy. In order to eliminate bodyweight as a factor in tissue weight 
normalization, tibial length, which remains constant throughout adulthood, was 
measured and served as a normalizer [171].  
Samples for histology were submersed in a fixative solution of 10% 
formaldehyde. After the initial fixation step, samples underwent dehydration (using 
ethanol in decreasing percentages), diaphanisation (using xylene) and impregnation in 
liquid paraffin (54 ° C). Later they were placed and properly oriented in metal molds, 
and serial sections of 4 μm and 3 μm were obtained from RV and pulmonary arteries, 
respectively, in a Minot type microtome.  
Haematoxylin and eosin (HE) stained sections of RV were digitally 
photographed (Olympus XC30 Digital colour Camera) and cardiomyocyte cross-
sectional area and diameter were measured using imaging software (cell^B, Olympus). 
Fifty muscle fibers per animal were analyzed and only nuclei-centered cardiomyocytes 
were considered for analysis. 
Sirius Red staining, which stains collagen fibers, was used to determine fibrosis 
on RV sections. Digital images were analyzed using image analysis software (Image-
Pro Plus version 6.0, Media Cybernetics Inc.). Seven randomly selected fields were 
analyzed per animal by two blinded observers. 
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Van Gieson staining, which distinguishes smooth muscle from collagen fibers, 
was used to determine the area and thickness of pulmonary artery sections. Images 
were acquired and analyzed as previously mentioned. 
 
Molecular studies 
Total mRNA from cardiac tissue samples was extracted  after homogenization 
in a metal mortar (~800 rpm rotor), through the guanidinium thiocyanate silica-gel 
membrane-binding method according to the manufacturer’s instructions (Quiagen 
74124) [163,172],. Sample purity (as assessed by the 260/280 nm absorption ratio) 
and total mRNA concentration were assayed by spectrophotometry (Eppendorf 
6131000.012). Two-Step real-time RT-PCR was used for relative mRNA quantification. 
For each studied gene, standard curves were generated based on the correlation 
between the quantity of starting total mRNA and the PCR threshold cycle (second 
derivate method) of successive dilutions of a random rat cardiac tissue sample 
(r≥0,98). Equal amounts of total mRNA from every sample (50 ng) underwent three 
separate two-step real time RT-PCR experiments with specific primers for each gene. 
RT was performed using a standard thermocycler (Whatman Biometra 050-901), in a 
total volume of 20µL, with 40U/reaction of reverse transcriptase (invitrogen 18064-014), 
20U/reaction of RNase inhibitor (Promega N2515), 30ng/mL random primers 
(invitrogen 48190-011), 0,5mM nucleotide mix (MBI Fermentas R0192), 1,9mM MgCl2, 
and 10mM DTT, at 22°C, 50°C and the 95°C, for 10, 50, and 10 minutes, respectively. 
PCR was performed with 2µL cDNA as template in a total volume of 20µL (LightCycler 
II®, Roche), using hot-start polymerase and SYBR green as marker (Quiagen 204143) 
according to the manufacter’s instructions. Melting curve analysis of each PCR reaction 
was performed to exclude primer-dimer formation and to assess the purity of the 
amplification product.  
The results of mRNA quantification are expressed in arbitrary units (AU), the mean of 
CTRL group after normalization for GAPDH corresponding to 1 AU. The primer pairs 
used to quantify genes were: GAPDH – P1-5’TGGCCTTCCGTGTTCCTACCC3’, P2-
5’CCGCCTGCTTCACCACCTTCT3’; NRG-1 – 
P15’AAGCTGGCCATTACGTAGTTTTG3’, P2-5’TGT 
GCGGAGAAGGAGAAAAACTTTC3’; ET-1 - P15’CGGGGCTCTGTAGTCAATGTG3’, 
P2-5’CCATGCAGAAAGGCGAATGTC3’; BNP - 
P15’CAGAGCTGGGGAAAGAAGAG3’, P2-5’GGACCAAGGCCCTACAAAAGA3’. 
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Statistical analysis 
Statistical analysis was performed using GraphPad Software (vs.5). 2-way 
ANOVA was used to statiscally analyse all the presented parameters, except 
endothelial function which underwent a 2-way repeated measures ANOVA test. Holm-
Sidak’s method was performed for post hoc comparisons between groups. Group data 
are presented as means±SEM and were compared using two-way ANOVA. Differences 
with p<0,05 were considered statistically significant. 
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RESULTS 
Echocardiographic evaluation 
 The full echocardiographic analysis is presented in Table 4. MCT-treated 
animals developed RV hypertrophy, as indirectly measured by 2-dimentional M-mode 
analysis of the interventricular septum thickness (IVSDD), while no statistically 
significant changes occurred in the LV free wall thickness. Left ventricle end diastolic 
diameter (LVEDD) was decreased in the MCT group.  Treatment with rhNRG-1 
resulted in reversal of RV remodeling, although LVEDD was not significantly reverted. 
 Doppler imaging analysis revealed a deficit on the right heart flow. Pulmonary 
flow was altered in the pulmonary hypertensive animals, as shown by the decreased 
pulmonary flow velocity (PAPSV), acceleration time (PAAT) and velocity time integral 
(PAVTI) when compared with healthy animals. The ratio PAAT/ejection time (PAET) 
was also altered in the MCT group. Treatment with rhNRG-1 restored velocity and 
acceleration time of blood flow in the pulmonary artery, normalizing the PAAT/PAET 
ratio. 
 Transvalvular flow analysis revealed the presence of both pulmonary and 
tricuspid regurgitation associated with pulmonary hypertension, where MCT animals 
presented reverse flow through both the tricuspid (2.530 ± 0.608 vs. 0.609 ± 0.059, 
MCT vs. CTRL) and pulmonary valves (0.888 ± 0.288 m/sec, no reverse flow was 
detected in other groups besides MCT). Treatment with rhNRG-1 decreased tricuspid 
incapacity and eliminated pulmonary insufficiency. 
 Right atria area was also increased in MCT animals and a tendency was 
observed in the tricuspid annular plane systolic excursion (TAPSE) to be increased in 
the same group. Pharmacological rhNRG-1 intervention also normalized both these 
parameters. 
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Table 4 – Echocardiographic evaluation 
 CTRL MCT 
 
vehicle rhNRG-1 vehicle rhNRG-1 
LVPWDD (mm) 1.40 ± 0.07 1.41 ± 0.08 1.49 ± 0.11 1.31 ± 0.11 
LVEDD (mm) 6.93 ± 0.10 6.86 ± 0.20 5.87 ± 0.43
*
 6.41 ± 0.12 
IVSDD (mm) 1.478 ± 0.097 1.633 ± 0.078 2.150 ± 0.141
*
 1.667 ± 0.119
#
 
LVEF (%) 86.48 ± 1.25 87.99 ± 1.88 89.43 ± 2.41 89.57 ± 1.63 
APSV (m/s) 0.98 ± 0.04 0.97 ± 0.07 0.80 ± 0.04
*
 0.86 ± 0.02
*#
 
PAPSV (m/s) 1.06 ± 0.04 1.08 ± 0.02 0.87 ± 0.04
*
 0.98 ± 0.02
# 
PAAT (ms) 28.74 ± 1.28  28.55 ± 0.91 19.41 ± 2.17
*
 25.48 ± 1.79
#
 
PAAT/PAET 0.32 ± 0.01 0.31 ± 0.01 0.21 ± 0.03
*
 0.27 ± 0.04
#
 
PAVTI 6.04 ± 0.23 6.29 ± 0.17 4.43 ± 0.48
*
 5.61 ± 0.19
#
 
RVEDD (mm) 5.00 ± 0.07  5.10 ± 0.23 5.32 ± 0.21 5.00 ± 0.20 
RAA (cm
2
) 0.13 ± 0.02 0.12 ± 0.01 0.22 ± 0.02
*
 0.14 ± 0.01
#
 
TAPSE (cm) 0.18 ± 0.01 0.17 ± 0.03 0.22 ± 0.02 0.18 ± 0.03 
APSV – aortic peak systolic velocity; LVEF – left ventricle ejection fraction; SF – shortening fraction; IVSDD – 
interventricular septum diastolic diameter; LVEDD – left ventricle end diastolic diameter; LVPWDD – left ventricle 
posterior wall diastolic diameter; PAAT – pulmonary artery acceleration time; PAAT/PAET – pulmonary acceleration 
time / pulmonary artery ejection time; PAPSV – pulmonary artery peak systolic velocity; PAVTI – pulmonary artery 
velocity time integral; RAA – right atria area; RVEDD – right ventricle end diastolic diameter; TAPSE – tricuspid annular 
plane systolic excursion. 
*
p < 0.05 vs CTRL + vehicle; 
#
p < 0.05 vs MCT + vehicle. 
 
Figure 3 – Transthoracic echocardiographic analysis. Representative images from the CTRL + vehicle (A,E,I), 
CTRL + rhNRG-1 (B,F,J), MCT + vehicle (C,G,K) and MCT + rhNRG-1 (D,H,L) groups showing the pulmonary flow 
pattern (A-D), apical 4-chamber view (E-H) and parasternal short-axis view (I-L). In the apical 4-chamber and 
parasternal short-axis view white arrows represent the interventricular spetum. MCT + vehicle animals reveal the 
presence of a midsystolic notch (white arrow in image C) and a deviation of the IVS to the left side of the heart (white 
arrows in images E-L). Treatment with rhNRG-1 restored both pulmonary waveform (D) and IVS structure (H and L). 
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Invasive hemodynamic evaluation 
Heart catheterization evaluation showed that several parameters of both 
systolic and diastolic function were altered in MCT animals (Table 5). Both end-systolic 
and end-diastolic RV pressures increased, and cardiac output was compromised in 
pulmonary hypertensive animals. Pharmacological rhNRG-1 treatment significantly 
improved all the above mentioned parameters. 
MCT-injected animals revealed impaired diastolic function, both by 
compromised relaxation, as measured by dP/dtmin, and increased RV stiffness, as 
measured by the end-diastolic pressure volume relationship (k1). Systolic function was 
improvedas shown by the increased RV contractility, as measured by dP/dtmax, and the 
by end systolic pressure volume relationship (slope(Emax)). rhNRG-1 treatment led to an 
attenuation of both diastolic dysfunction and increased inotropy that were observed in 
the MCT group. 
Considering the LV, systolic pressures were decreased in the MCT group and 
diastolic dysfunction was also evident, as revealed by the decrease in the -dP/dtmin and 
the increase in the isovolumic relaxation time. Treating rats with rhNRG-1 increased 
maximum developed pressures and improved diastolic function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
Table 5 – Left Ventricle and Right ventricle hemodynamic evaluation 
 CTRL MCT 
RV vehicle rhNRG-1 vehicle rhNRG-1 
P
máx
 (mmHg) 32.9 ± 2.3 34.0 ± 2.1 58.8 ± 4.0
*
 49.0 ± 3.6
*#
 
CO (mL.min
-1
) 64.3 ± 17.2 62.0 ± 6.8 40.0 ± 18.7
*
 53.7 ± 9.0
*#
 
EDP (mmHg) 2.26 ± 1.29 2.38 ± 0.37 4.66 ± 3.94
*
 2.47 ± 1.29
#
 
dP/dtmax (mmHg.s
-1
) 2262 ± 134 2301 ± 152  3519 ± 205
*
 2917 ± 199
#
 
-dP/dt
min
 (mmHg.s
-1
) 2199 ± 145 1760 ± 107 3050 ± 195
*
 2484 ± 246
#
 
LV     
Pmax (mmHg) 126.1 ± 3.4 118.6 ± 4.5 96.2 ± 5.9
*
 104.5 ± 4.8
*#
 
-dP/dtmin (mmHg.s
-1
) 10267 ± 626 9207 ± 404 4762 ± 585
*
 6823 ± 972
*#
 
 (ms) 8.27 ± 0.50 7.99 ± 0.15 10.77 ± 0.72
*
 9.14 ± 0.55
#
 
IVC occlusions 
RVESPVR (linear) 
    
Slope  (Emax), (mmHg.µL
-1
) 0.14 ± 0.04 0.17 ± 0.09 0.9 ± 0.28
*
 0.29 ± 0.05
*#
 
RVEDPVR (exponential) 
    
k
1
 0.006 ± 0.004 0.005 ± 0.001 0.019 ± 0.005
*
 0.008 ± 0.001
#
 
dP/dtmax–EDV (mmHg .s
-1
.µL
-1
) 9.97 ± 2.41 10.12 ± 5.32 28.29 ± 6.08
*
 16.57 ± 5.77
#
 
LVEDPVR (exponential)     
k
1
 0.01 ± 0.00 0.01 ± 0.00 0.03 ± 0.01 0.01 ± 0.00 
Left (LV) and Right Ventricular (RV) hemodynamic evaluation of control vehicle treated (CTRL + vehicle), control treated 
with recombinant human NRG-1 (CTRL + NRG-1), monocrotaline-injected treated with vehicle (MCT + vehicle) and 
monocrotaline-injected treated with recombinant human NRG-1 (MCT + NRG-1) rats. CO - cardiac output; dP/dtmin/max 
minimum and maximum rate of pressure change; EDP -  end-diastolic pressure; EDPVR – end-disatolic pressure 
volume relationship. ESPVR -  end-systolic pressure-volume relationship; Pmax – maximum pressure;  - time constant 
of isovolumetric relaxation; 
*
p < 0.05 vs. CTRL + Vehicle and 
# 
p < 0.05 vs. MCT + vehicle. 
 
In vitro studies in isolated skinned cardiomyocytes 
The analysis of the total force development showed that MCT group isolated RV 
cardiomyocytes were able to develop higher force than the CTRL group cells (17.71 ± 
5.83 vs. 13.85 ± 3.96 N/m2, MCT vs. CTRL) (Figure 4-A). In cardiomyocytes from 
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rhNRG-1 treated rats’ total developed force was significantly lower than in the MCT 
group cells and similar to CTRL group cardiomyocytes (12.59 ± 3.15 N/m2). 
MCT-group isolated cardiomyocytes developed higher passive force when 
compared to CTRL group cells, at the sarcomere lengths of 2.0 (1.76 ± 0.26 vs. 1.43 ± 
0.29 N/m2, MCT vs. CTRL), 2.2 (3.74 ± 0.71 vs. 2.68 ± 0.24 N/m2, MCT vs. CTRL), and 
2.3 µm (5.73 ± 1.22 vs. 3.86 ± 0.87 N/m2, MCT vs. CTRL). Treatment with rhNRG-1 
was able to significantly restore the passive force development to levels similar to the 
CTRL group cardiomyocytes (1.28 ± 0.25, 3.04 ± 0.55, and 3.63 ± 0.89 N/m2, at 2.0, 
2.2, and 2.3 µm respectively). The CTRL + rhNRG-group cardiomyocytes developed 
significantly less passive force when compared to CTRL group cells (1.19 ± 0.25, 2.32 
± 0.55, and 3.16 ± 0.54 N/m2, at 2.0, 2.2, and 2.3 µm, respectively) as represented in 
Figure 4-B. 
Active force was also increased in cardiomyocytes from MCT animals when 
compared to controls (14.39 ± 1.47 vs. 11.10 ± 0.41 N/m2, MCT vs CTRL), rhNRG-1 
chronic treatment resulted in no differences from healthy animals (9.67 ± 0.67 N/m2) as 
represented in Figure 4-C. 
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Figure 4 – Permeabilized isolated cardiomyocyte force development. MCT group animals showed higher levels of 
total force development (A) when compared to the CTRL group. Passive force evaluated at 2.0, 2.2 and 2.3 mm of 
sarcomeric length (B) showed increased development of passive force in the MCT group. Active force development was 
higher in the MCT group when compared to the CTRL group (C). MCT + rhNRG-1 animals showed no differences from 
the CTRL group in total, passive and active force. * p < 0.05 in line-targeted groups. 
 
In vitro studies in vascular preparations 
Endothelial dysfunction, due to MCT-induced pulmonary hypertension was 
present in MCT animals, as shown by the impaired relaxation of pulmonary arterial 
rings to increasing doses of acetylcholine (35.41 ± 4.02 vs. 86.27 ± 1.85 %, MCT vs. 
CTRL), with significant increase of the EC50 (6.69x10-7 ± 1.41x10-7 vs. 1.95x10-7 ± 
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3.93x10-8 M, MCT vs. CTRL). Pulmonary rings from rhNRG-1 treated animals showed 
improved endothelial function (48.31 ± 5.67 % and 2.45x10-7 ± 6.30x10-8 M) when 
compared to untreated pulmonary hypertensive animals (Figure 5). 
 
Figure 5 – Pulmonary arterial endothelial function evaluation. Pre-contracted arterial ring (10
-5
 M phenylephrine) 
submitted to acetylcholine (10
-9
 to 10
-5
M) showed decreased relaxation in the MCT group when compared to the CTRL 
group. MCT + rhNRG-1 animals showed improved relaxation when compared to the MCT group. EC50 was increased in 
the MCT animals, while treatment with rhNRG-1 normalized the EC50 value. * p < 0.05 vs. CTRL + vehicle; 
#
 p < 0.05 
vs. MCT + vehicle, 
§
 p < 0.05 in line-targeted groups. 
 
Morphometric and histological analysis 
Induction of pulmonary hypertension gave rise to heart hypertrophy (4.26 ± 0.14 
vs. 3.10 ± 0.06 g/kg, MCT vs. CTRL) which was accounted to RV hypertrophy with an 
increase in the RV weight / body weight ratio (1.21 ± 0.03 vs. 0.55 ± 0.02 g/kg, MCT vs. 
CTRL), RV weight / tibia length ratio (0.076 ± 0.002 vs. 0.045 ± 0.001 g/cm, MCT vs. 
CTRL) and RV weight / LV + Septum ratio (0.53 ± 0.02 vs. 0.27 ± 0.01 g/kg, MCT vs. 
CTRL). Lung weight was also increased (0.742 ± 0.034 vs. 0.436 ± 0.021 g/cm, MCT 
vs. CTRL) in pulmonary hypertensive animals. Gastrocnemius liver weight showed no 
differences between groups. rhNRG treated animals presented decreased ventricular 
remodeling (0.057 ± 0.003 g/cm) and lung weight (0.618 ± 0.036 g/cm) as presented in 
Table 6. 
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Table 6 – Morphometrical analysis 
 CTRL MCT 
 
vehicle rhNRG-1 Vehicle rhNRG-1 
HW/BW (g/kg) 3.10 ± 0.06 3.12 ± 0.06 4.26 ± 0.14
*
 3.43 ± 0.11
#
 
RVW/BW (g/kg) 0.55 ± 0.02 0.58 ± 0.83 1.21 ± 0.03
*
 0.83 ± 0.06
*#
 
RVW/LV+SW (g/g) 0.27 ± 0.01 0.29 ± 0.01 0.53 ± 0.02
*
 0.40 ± 0.02
*#
 
RVW/TL (g/mm) 0.05 ± 0.00 0.05 ± 0.00 0.08 ± 0.00
*
 0.06 ± 0.00
*#
 
LW/TL (g/mm) 0.44 ± 0.02 0.41 ± 0.01 0.74 ± 0.03
*
 0.62 ± 0.04
*#
 
LiW/TL 2.58 ± 0.08 2.59 ± 0.17 2.29 ± 0.13 2.58 ± 0.11 
GcW/TL 51.49 ± 1.56 49.92 ± 2.44 44.69 ± 1.45 45.78 ± 1.44 
BW – body weight; GcW – gastrocnemius; HW – heart weight; LiW – liver weight; LV+SW – left ventricle + septum 
weight; LW – lung weight; RVW – right ventricle weight; TL – tibia length; 
*
p < 0.05 vs CTRL + vehicle; 
#
p < 0.05 vs MCT 
+ vehicle. 
RV remodeling was further confirmed by increased cardiomyocyte cross 
sectional area and diameter (536.67 ± 59.46 mm2 and 25.35 ± 1.19 mm vs. 375.39 ± 
47.43 mm2 and 20.84 ± 1.02 mm, MCT vs. CTRL, respectively) in diseased animals, 
while rhNRG treatment decreased cardiomyocyte hypertrophy (409.01 ± 19.72 mm2 
and 22.18 ± 0.61 mm) as represented in Figures 6-7. 
 
Figure 6 - Histological analysis of cardiomyocyte structure. Light microscopy images of hematoxylin-eosin stained 
sections of RV (400x) from CTRL + vehicle (A), CTRL + rhNRG-1 (B), MCT + vehicle (C) and MCT + rhNRG-1 (D). 
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Figure 7 – Quantification of cardiomyocyte dimensions. MCT group animals showed an increased cardiomyocyte 
diameter (A), and cross sectional area (B), when compared to control animals. MCT + rhNRG-1 animals showed no 
differences from the CTRL group, which was also not different from the CTRL + rhNRG-1 group. * p < 0.05 in line-
targeted groups.  
Histological analysis of pulmonary arteries revealed pulmonary hypertension 
associated vascular remodeling, specifically thickening of the tunica media (53.70 ± 
1.11 vs. 31.37 ± 0.59 mm, MCT vs. CTRL) as seen in Figure 9-A. Media area/ lumen 
area ratio was also increased in MCT animals (41.19 ± 1.00 vs. 31.89 ± 1.84 %, MCT 
vs. CTRL, Figure 9-B). Administration of rhNRG-1 resulted in reversal of the detected 
remodeling (34.26 ± 0.61 mm and 30.33 ± 1.74 %). 
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Figure 8 – Histological analysis of pulmonary arterial rings structure. . Light microscopy images of hematoxylin-
eosin stained sections of pulmonary arterial rings (63x) from CTRL + vehicle (A), CTRL + rhNRG-1 (B), MCT + vehicle 
(C) and MCT + rhNRG-1 (D). 
 
Figure 9 – Quantification of  pulmonary arterial rings media thickness. MCT group showed increased thickness of 
the media layer (A) and the media layer area / lumen area ratio (B), while the rhNRG-1 group showed non-significant 
differences from the CTRL group. * p < 0.05 in line-targeted groups. 
Compared to healthy animals, MCT animals showed increased fibrosis in the 
RV (2.04 ± 0.17 vs. 0.98 ± 0.07 %, MCT vs. CTRL), while MCT treated rats showed no 
differences from the control group (1.00 ± 0.17 %) as represented in Figures 10-11. 
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Figure 10 –Histological analysis of RV fibrosis. Light microscopy images of sirius red stained samples of RV (400x) 
from CTRL + vehicle (A), CTRL + rhNRG-1 (B), MCT + vehicle (C) and MCT + rhNRG-1 (D). 
 
 
Figure 11 – Quantification of RV fibrosis. MCT group animals showed increased fibrosis when compared to CTRL 
animals, while MCT + rhNRG-1 are not different from the CTRL group. rhNRG-1 did not increase fibrosis in CTRL 
animals (C). * p < 0.05 in line-targeted groups. 
 
Molecular studies 
The RV from MCT animals presented increased mRNA expression of brain 
natriuretic peptide (BNP) and endothelin (ET)-1 (17.46 ± 2.18 vs. 1.00 ± 0.42, 5.03 ± 
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1.24 vs. 1.00 ± 0.21 AU, MCT vs. CTRL, respectively), as illustrated in Figure 12-A,B. 
Endogenous levels of NRG-1 expression were also higher in the MCT animals (11.05 ± 
2.85 vs. 1.00 ± 0.30 AU, MCT vs. CTRL). These changes were attenuated or reversed 
in the MCT + rhNRG-1 group (5.57 ± 1.99, 1.73 ± 0.66, 0.73 ± 0.36, respectively) as 
represented in Figure 12-C. Treating MCT animals with bosentan resulted in decreased 
levels of NRG-1 when compared with MCT animals (3.79 ± 1.47 vs. 11.05 ± 2.85 AU, 
MCTBOS vs. MCT).  
 
Figure 12 – mRNA quantification of BNP, ET-1 and NRG-1 in the RV. MCT group showed increased expression of ET-1 
(A), while the rhNRG-1 group showed significantly lower levels of expression. The MCT group also showed increased 
expression of BNP (B) while the rhNRG-1 group showed no significant differences from the CTRL group. NRG-1 levels 
were increased in the MCT group (C) and treatment with rhNRG-1 resulted in no differences from the CTRL animals. 
Treating MCT animals with bosentan resulted in decreased levels of NRG-1 expression when compared to the MCT 
group. * p < 0.05 in line-targeted groups. 
 
 
47 
 
DISCUSSION 
 
rhNRG-1 treatment improves RV and LV function in MCT-induced pulmonary 
hypertension 
In this work we demonstrated that chronic treatment with intraperitoneal 
administration of rhNRG-1, in a model of MCT-induced PAH, enhances both LV and 
RV function, improving CO and attenuating increased overload-dependent systolic and 
diastolic dysfunction. 
 Several studies have demonstrated the progression of MCT-induced pulmonary 
hypertension using several indexes of RV function and structure through 
echocardiography. 
 Non-invasive methods to evaluate RV function and severity of PAH are of major 
importance and allow a comparable approach to that used more routinely in patients. 
 Transthoracic echocardiography is used to assess temporal evolution of cardiac 
dysfunction in PAH [173-175], specifically pulmonary waveform and flow. In MCT-
induced PAH there’s a development of a midsystolic notch in the pulmonary artery flow 
waveform (which corresponds to the findings we have observed in our study – Figure 
1) together with quantifiable reverse flow (pulmonary regurgitation), and decreased 
acceleration time. Coinciding, we have also observed a decrease in PAAT which 
significantly altered the PAAT/PAET ratio, and systolic flow which is compromised in 
PAH  and is associated with pulmonary systolic pressures [176] and correlates with 
decreased survival in PAH patients [177]. Treating rats with rhNRG-1 resulted in the 
absence of pulmonary midsystolic rapid deceleration, observed by the absence of a 
misystolic notch in the pulmonary waveform of MCT+NRG-1 animals (Figure 1). 
Pulmonary flow velocity and acceleration time were also restored with rhNRG-1 
pharmacological intervention, revealing an improved pulmonary arterial function and 
decreased RV afterload. 
 Similarly to previous studies [173], we observed a trend towards RV chamber 
dilation, nevertheless significance was not achieved (data not shown). This might easily 
be explained by the stage at which the animals were analyzed (21-24 days after MCT 
administration). At this time point, the RV, in response to increased pulmonary vascular 
resistances, presents a non-dilated, adaptive concentric hypertrophied chamber. In 
fact, Hardziyenka et al [178] have shown that right ventricular end-diastolic diameter, 
measured by echocardiography seems to start to increase between 20-25 days post 
MCT administration. This study showed that, in response to increased pressure-
overload, there is a shift of the intraventricular septum to the left side chamber, 
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agreeing with our observations (Figure 1). NRG-1 therapeutic intervention attenuated 
the adaptive hypertrophy, improving RV structure, as well as correcting intraventricular 
septum ablation. 
In PAH, not only RV function is impaired, LV function might also be impaired 
due to ventricular interaction and decreased right sided function [19]. Therefore it is 
crucial to evaluate the LV in the context of PAH [179], whose diastolic impairment is 
closely related to PAH severity, as evaluated by echo-doppler [180]. We observed a 
significant decrease in LVEDD as well as decreased aortic flow velocity, corroborating 
the effect that unloading of the LV through RV alterations in PAH has on the left side 
function [31]. 
Although no studies have invasively evaluated NRG-1’s chronic treatment effect 
on RV function in PAH, enough studies have been performed on the LV that allow us to 
explain our results.  Cardiac performance was improved by NRG-1 administration in 
several models of cardiovascular disorders. Liu et al [147], used models of myocardial 
ischemia, anthracycline-induced cardiomyopathy, and chronic pacing, and showed that 
NRG-1 treatment leads to attenuation of contractile dysfunction. LVEF and LVESP 
were decreased, as well as dP/dtmax with animals with heart failure, while treated 
animals showed improvements in all parameters. Diastolic function was also preserved 
with treatment as measured by LVEDP and dP/dtmin [147]. In diabetic cardiomyopathy 
animal models, NRG-1 treatment also resulted in improvement of both systolic and 
diastolic function [151]. Similarly, and despite all the structural differences between the 
LV and the RV, our results in the RV function match what has been previously 
described for the LV. MCT-injected animals revealed a severe cardiac dysfunction 
secondary to PAH. MCT animals presented RV hypercontractility, as shown by highly 
increased systolic pressures, as well by changes in other parameters of contractile 
function, namely dP/dtmax and inferior vena cava occlusion-derived ESPV relationship’s 
slope. Diastolic dysfunction was also present in the RV of MCT animals, shown by 
increased stiffness (rise in RVEDP) and impaired relaxation (decreased RV – dP/dtmin). 
These hemodynamic alterations correspond to an initial compensatory myocardial 
hypertrophy of the RV in response to pressure overload resulting from increased 
pulmonary vascular resistance, as described in previous works [181]. 
As earlier mentioned, LV dysfunction is associated with PAH and RV pressure 
overload [30,31]. Our echocardiographic analysis revealed altered LV structure in PAH 
induced animals which might result in altered diastolic and systolic function. Moreover, 
ventricular interaction is responsible for RV-dependent alterations of the LV [32], and 
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both animal [182] and human [30] data have demonstrated that systolic function is 
impaired in RV pressure overload. 
Our data have also showed that not only the RV was affected, but also the left 
side of the heart presented both systolic and diastolic dysfunction secondary to the 
pressure-overloaded RV. Contractile capacity was compromised as well as cardiac 
output, and diastolic function impaired with decreased d/dtmin, increased 𝛕 and 
increased EDPVR-derived slope (k1). 
Treating MCT animals with NRG-1 resulted in the improvement of RV and LV 
function. Both systolic and diastolic dysfunction of the RV and the LV were improved 
and both ventricles showed enhanced contractile and relaxation functions. 
Cardiac catheterization allowed for a more detailed analysis of ventricular 
function, and corroborated echocardiographic data, nevertheless one has to be careful 
when interpreting the results and extrapolating previous knowledge from the LV and 
using them to explain RV pathophysiology [19]. 
Stem cell treatment improves RV function in the MCT-induced model of PAH 
[183,184], as well as in a biventricular failure model [185]. Taking into account that 
NRG-1 plays a key role in the differentiation of cardiomyocytes [113,114], this could be 
a very interesting new approach in the understanding and development of NRG-1 
associated treatment of PAH. In fact, further comprehension of these effects in human 
patients is not that far away since RV-associated disorders are already producible at a 
cell culture level [186], creating new research possibilities. 
Myocardial hypertrophy is accompanied by a significant increase in the content 
of extracellular matrix proteins, therefore a change in tension development seen in 
multicellular preparations may be due merely to a change in the number of force-
generating elements per cross-sectional area of myocardium, without an actual change 
in intrinsic contractile protein function. Thus, it was important to complement our 
hemodynamic data with the information gathered from skinned cardiomyocytes in the 
absence of confounding influences of extracellular matrix components. 
Pressure-overload on the RV results in increased sarcomeric stiffness [187]. 
Our evaluation of single cell contractile machinery showed increased stiffness in MCT-
induced PAH, as cardiomyocytes from the MCT group revealed increased passive 
force development at several sarcomeric lengths, confirming at the cellular level, what 
had been previously described in our in vivo analysis, and suggesting that the 
increased stiffness and impaired relaxation of the RV in PAH is in part due to increased 
sarcomere stiffness. Active force enhancement further corroborates the RV 
hypercontractile state in response to pressure-overload observed in our model.  
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Protein kinase C-alpha phosphorylation of titin leads to increased passive 
tension [188], and on the onset of PAH, in animal models, its expression levels are 
increased [189,190]. In the MCT-induced PAH model, increased oxidative stress, 
through reactive oxygen species production is associated with RV failure [191], and 
also increases titin stiffness through disulfide bonding in a N2B specific sequence 
[192], which might explain the observed increased passive tension in cardiomycoytes 
isolated from theMCT groupBoth phosphorylation of titin domains, and titin isoform 
shifting to the less compliant isoform (N2B) are associated with neurohumoral 
activation [193], that is present in MCT-induced PAH [163]. 
Our pharmacological intervention resulted in improved intrinsic myocardial 
performance, attenuation of the increased stiffness observed in MCT cardiomyocytes, 
as well as of the overdevelopment of active force. Attenuated stiffness in the MCT + 
rhNRG-1 group could be explained by the cardioprotective effects of NRG-1 through 
oxidative stress reduction [194,195]. 
Taking all the functional evaluations into account, we can clearly state that 
rhNRG-1 significantly improves RV function both at the intrinsic myocardial function 
level, ventriculo-arterial coupling, with improved blood pumping capability and improved 
pulmonary flow patterns. 
Interestingly CTRL + rhNRG-1 skinned cardiomyocytes revealed decreased 
passive tension when compared to the CTRL + vehicle group, demonstrating an effect 
of NRG-1 in non-pathological conditions over sarcomeric determinants. A possible 
mechanism through which passive tension decreases in control treated animals is the 
protein kinase G-dependent phosphorylation of a serine residue within the N2B 
fragment of titin [196], through NRG-1 mediated activation of PI3K/Akt and eNOS 
[124,197], leading to a decreased stiffness of the cardiomyocyte myofibrils.  
Therefore, NRG-1 may ameliorate RV compliance and diastolic function by 
affecting the sarcomeric protein titin and by activation of the eNOS, both powerful 
determinants of ventricular compliance. 
 
PAH-associated pulmonary vascular dysfunction and remodeling is attenuated 
with rhNRG-1 treatment 
PAH is associated with an imbalance of endothelial production of various 
mediators, resulting in endothelial dysfunction [42]. In the MCT model of PAH, a severe 
endothelial dysfunction is observed [168,198,199], since once metabolized in the liver, 
the originated active metabolite (monocrotaline pyrrole) destroys the endothelial layer 
of pulmonary arteries, and induces vascular remodeling, typical of pulmonary 
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hypertension [73,77,200], in a similar way to human pathology [201] This is 
characterized by an impairment in vasorelaxation in response to the well-known 
endothelium-dependent vasodilator acetylcholine [202]. 
In fact, in our study pulmonary arteries from MCT-injected animals presented 
endothelial dysfunction, as they were unable to relax in response to acetylcholine, 
presenting an increased EC50. These changes might be explained by either an 
unavailability of acetylcholine receptors or a functional inhibitory effect, through an 
opposite constrictive response or negative modulation of vasodilatory signaling. 
Interestingly, in pulmonary vascular dysfunction, there’s an impaired vasodilatory 
response through acetylcholine that is mediated by upregulation of the muscaric 
acetycholine receptor M1 [203]. Upon stimulation M1 receptor leads to vasoconstriction 
in opposition to the vasodilataroy response associated with the binding of acetylcholine 
to the M3 receptor [204], which is dependent on cGMP/eNOS activation. Although 
controversy exists, some studies have shown that eNOS is downregulated in 
pulmonary arteries and/or lungs from both animals [205-207] and patients [208] with 
PAH, including MCT-induced PAH [209,210], and its interaction with intracellular 
regulatory proteins is also compromised [211].  
On the other side, phosphodiesterase-1, which is upregulated in PAH [212,213], 
is activated through inositol triphosphate-mediated intracellular calcium release, in 
response to M1 receptor activation. This enzymatic activation leads to cGMP 
degradation [214], and might lead to depressed levels of cGMP-dependent NO 
production. 
In our study, chronic treatment with rhNRG-1 resulted in improved pulmonary 
arterial endothelial function, which might be a result of increased eNOS activation 
[215]. Nevertheless, further studies need to be performed in order to determine which 
signaling pathways are altered in our animal model of PAH, and if eNOS activation 
through NRG-1/ErbB signaling is the major contributor to the improved endothelial 
function. 
Besides endothelial dysfunction, vascular remodeling was also observed in 
pulmonary arteries from the MCT-injected animals, through thickening of the smooth 
muscle cell comprised media layer.  
The media area/lumen area ratio gives us a more detailed analysis of the 
structural changes happening at the pulmonary arteries. Maximum vasodilation should 
be achieved prior to histological analysis of the arteries, in order to exclude bias in 
lumen area in vasoconstricted arteries [216]. 
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Despite significant increase in medial thickness, no differences in lumen area 
were observed (data not shown), revealing that remodeling of the pulmonary arterial 
wall, and not decrease in lumen are taking place in our model of MCT-induced PAH. 
This finding suggests that the major role in the increase of PVR is a functional 
decrease of the arterial diameter (vasoconstriction) instead of a structural one (lumen 
area decrease). 
In fact, in our study both measurements reveal increased muscularization of the 
media layer in MCT-induced PAH animals and, rhNRG-1 treatment resulted in the 
attenuation of pulmonary vascular remodeling. Intervention with rhNRG-1 completely 
normalized tunica media thickness, as no significant remodeling was observed in 
treated animals, diminishing the pulmonary vasculature-imposed overload on the RV.  
These results do not differ from other studies that have shown the effect of 
pharmacological treatment in pulmonary hypertension models, through pulmonary 
artery remodeling and improved endothelial dysfunction [217-219], and might not come 
as a surprise, since rhNRG-1 treatment leads to decreased neointima formation and 
vascular smooth cell proliferation after vascular injury in other vascular beds [131]. 
 
MCT-induced RV morphohistological changes are attenuated by rhNRG-1 
treatment 
rhNRG-1 treatment after PAH-induction resulted in accentuated decrease of 
cardiac hypertrophy, specifically RV hypertrophy, as well as lung congestion (Table 3). 
Heart weight was increased in PAH animals, as previously mentioned, and this was 
analyzed using the HW/BW ratio. Nevertheless, in PAH, the RV is the primary affected 
ventricle and therefore should be the focus of the analysis, since due to the augmented 
pulmonary vascular resistances it is under pressure overload. And in fact, the RVW/BW 
ratio was also increased in PAH animals, which revealed the presence of RV 
hypertrophy. 
 Despite being in agreement with all of our data regarding hypertrophy and 
hypertrophy-associated parameters measured, the model we’re using is associated 
with cachexia [17,21], and because of that, we alternatively measured the RV/TL ratio 
which is accepted as a reliable parameter for hypertrophy measurement [22]. The 
RVW/LV+SW ratio was consistent with the previously mentioned measurements. Lung 
edema and congestion is a consequence of PAH [220] and using the LW/TL ratio we 
observed an increase ratio in the MCT group, suggestive of PAH-associated lung fluid 
retention. 
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At the cellular level, our model of PAH developed cardiomyocyte hypertrophy, 
as measured by cardiomyocyte diameter and cross sectional area. These effects were 
however reverted by rhNRG-1administration. Reversal of hypertrophy in response to 
treatment underlines the functional recovery observed with non-invasive and invasive 
hemodynamic measurements. The RV of treated animals is under attenuated pressure-
overload and therefore, its adaptative hypertrophic response is decreased. Less 
muscle mass, less developed force and consequently, attenuated developed pressures 
and hypercontractile state. Decreased hypertrophy means decreased ventricular 
stiffness and improved diastolic function, both at the ventricle and the cardiomyocyte 
level. 
Although there is some controversy concerning the presence of interstitial 
fibrosis in the RV of MCT-injected animals [166,221,222] we have observed increased 
fibrosis in MCT animals, while treatment with rhNRG-1 resulted in reversal of fibrotic 
tissue deposition. Fibrotic tissue deposition in PAH aids the development of RV 
stiffness and contributes to its impaired diastolic function [163], therefore decreasing 
fibrosis is a major contribution of rhNRG-1 effect in preventing impaired RV relaxation. 
 
Increased expression of cardiac overload and hypertrophy markers are 
attenuated with rhNRG-1 treatment 
Cardiac overload and hypertrophy biomarkers were significantly increased in ill 
animals, when compared to controls. ET-1 plasmatic levels are elevated in PAH, 
associated with disease severity [223]. Moreover, its clearance from pulmonary arteries 
is reduced [224]. ET-1 levels are associated with the development of RV hypertrophy in 
MCT-induced PAH [82,225] and is increased in this experimental model [163,226]. In 
our study, RV ET-1 levels were augmented in pulmonary hypertensive rats up to 5-fold. 
Treatment with rhNRG-1 resulted in the reversal of ET-1 levels to control levels, 
completely abolishing its MCT-associated increase. 
Plasmatic BNP levels are associated with pulmonary hypertension [227] and its 
production is stimulated in response to pressure-overload [228] and are associated 
with the extent of RV dysfunction [229], being increased in MCT-injected animals [163]. 
In the present study, BNP expression in the RV of MCT animals is increased up to 15-
fold, and treatment reduces this enhancement by 10-fold. 
During the development of several cardiac pathologies in experimental models, 
NRG-1 cardiac expression rise, in an early stage [102,135,142,144], and in a later 
phase, when HF  is established, its expression drop [102,153]. Moreover, 
deleting/inhibiting NRG-1 and/or its signaling axis leads to increased susceptibility to 
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several cardiac-targeted experimental models [102,132,133,138,139]. Human 
plasmatic quantification has also shown that NRG-1 levels increase and correlate with 
HF functional class [156]. Although no studies have analyzed NRG-1 levels in the 
depressed RV, we have shown the increase of NRG-1 mRNA in the RV of rats with 
PAH induced by MCT, which accordingly to previously mentioned data 
[102,135,142,144] we interpret as a compensatory response to mechanical strain [215] 
and hypertrophy [230] induced by the increased pulmonary vascular resistances. 
Indeed, quantifying NRG-1 RV expression of 6 week post MCT-injection animals (data 
not shown) revealed lower mRNA expression than 4 week post MCT animals, which 
correlate with the decompensated, RV failure phase of PAH, where increased 
angiotensin II and epinephrine levels, associated with HF negatively regulate NRG-1 
expression [215]. 
Indeed, neurohumoral activation is associated with RV dysfunction in PAH 
[231]. While there is a downregulation of beta-adrenergic receptors [232] in late-stage 
MCT-induced PAH, both epinephrine and norepinephrine levels are increased 
[232,233]. The renin-angiotensin-aldosterone system is dysregulated in PAH [234], and 
contributes to pulmonary vascular remodeling [235]. Increased expression of the 
angiotensin-converting enzyme in pulmonary arteries of PAH patients [236] and 
increased activity in failing RVs [237], might account for the increased levels of 
angiotensin II. Dysregulation of neurohumoral mediators with increase of both 
epinephrine and angiotensin II results in an inhibiting effect on NRG-1 synthesis [215], 
explaining its downregulation in later stages of PAH with RV failure (6 week MCT 
animals). 
NRG-1 expression is induced in response to ET-1 action on endothelial cells 
[215,230], and this tight association was observed in our experimental groups, where 
higher expression levels of ET-1 and endogenous NRG-1 were observed in the MCT-
group, while treatment with NRG-1 led to a normalization of these levels. Also, treating 
MCT animals with bosentan, a non-selective ET-1 receptor antagonist led to decreased 
NRG-1 levels, confirming the connection between ET-1 stimulation and NRG-1 
increased synthesis. Nevertheless, the relation between ET-1 and NRG-1 is not clearly 
understood. While ET-1 increased coincided with NRG-1 increase, treatment with 
exogenous NRG-1 resulted in decreased ET-1 expression. While no explained 
mechanism justifies this result, an association between ETA (ET-1 receptor) and 
ErbB2/4 has been described [164], where colocalization of ETA and ErbB2/4 is 
determined to be the T-tubules in adult cardiomyocytes. This proximal physical 
localization, favors a physiological interaction, where ET-1-mediated stimulation inhibits 
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ErbB2/4 activation [164] in a one way manner (i.e. ETA activation inhibits ErbB2/4, 
while ErbB2/4 activation does not inhibit ETA). This inhibitory relationship confirms the 
relation between ET-1/NRG-1, and opens a possible detrimental mechanism for ET-1 
overexpression in PAH. Despite this, ET-1’s decreased levels in NRG-1 treatment are 
not answered for. One could hypothesize that being administered exogenously and at 
high dosages, NRG-1 can overcome the ET-1-mediated inhibitory effects and not only 
activate ErbB2/4, but exert some kind of negative regulation on ET-1/ETA signaling. 
On the other hand, simply by improving vascular function, as observed by the 
improved endothelial function of pulmonary arteries in MCT-induced PAH animals 
treated with NRG-1, and therefore reducing pulmonary vascular resistances, RV 
pressure overload was significantly attenuated. This means that decreased mechanical 
strain on the RV, which as mentioned above, has a stimulatory effect on NRG-1 
production and positively regulates ET-1 synthesis in endothelial cells [238]. Therefore, 
decreasing mechanical strain by NRG-1 treatment might be the link between ET-1 and 
NRG-1 decreased levels following treatment, nevertheless this association needs to be 
further studied. 
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CONCLUSION 
 
In conclusion, we show for the first time, in an experimental model of MCT-
induced PAH,   that rhNRG-1 treatment is able to restore PAH-induced severe 
abnormalities in cardiopulmonary function and structure.  
PAH is a chronic disease that is not always diagnosed early, therefore an 
increased interest is achieved in our approach where we begin treatment after PAH is 
established, revealing a more practical and clinical relevant therapy. 
The NRG-1/ErbB4 system has been thoroughly studied in the cardiovascular 
system, but research so far has failed to determine its effects on normal or diseased 
RV physiology, or pulmonary vascular function. We have set out and demonstrated the 
effects of an increase in NRG-1 levels through exogenous administration of the protein, 
which has shown that specific activation of ErbB receptors mediates several 
compensatory mechanisms that ameliorate the dysfunction and structural abnormalities 
associated with PAH. 
In spite of these results, further research is needed in order to determine 
specifically where NRG-1 plays its major role. Both ventricular and pulmonary function 
are altered, but since in this model RV dysfunction and eventual failure is secondary to 
pah, we cannot ascertain whether RV function and structure improvement is secondary 
to pulmonary vascular functional enhancement and therefore decreased vascular 
resistances, or if NRG-1 has a direct effect on the ventricle which by itself is capable of 
leading to the changes we observed. 
Although this question remains unanswered, the importance of this system in 
the RV, and more importantly in the pathophysiology of PAH is undeniable and 
therefore constitutes a major research interest. 
Also it is important to take into account that the animal model used in the 
present study does not mimic in its entirety human PH or PAH, nevertheless it has 
several pathophysiological alterations in common that allow us to enthusiastically point 
NRG-1 as a possible novel treatment for a very devastating, uncured and with an 
uncertain prognosis disease. 
We hope to have opened the road for further basic and translational research 
that could possibly lead to the establishment of rhNRG-1 as a novel and safe 
therapeutic agent for treating patients with PAH and RVHF. 
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